FDA Panel to Reconsider Safety of Diabetes Drug

Monday, 15 Apr 2013 08:08 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
A federal health advisory panel in June will reconsider safety data on GlaxoSmithKline Plc's Avandia diabetes drug, although the British drugmaker on Friday said it has not sought permission to make the nearly discontinued drug widely available again in the United States.
The U.S. Food and Drug Administration in September 2010 placed severe restrictions on use of the pill, due to heart attacks and deaths linked to the product, saying it should be available only to patients who cannot control their diabetes with any other drug. Glaxo estimates that only about 3,300 people in the United States still take the former blockbuster product.
 
Glaxo spokeswoman Mary Anne Rhyne said an item in the upcoming edition of the Federal Register said the FDA advisory panel will meet on June 5-6 to discuss the drug. She speculated the advisory panel will ask for an update from Glaxo on safety information it sought from the drugmaker in 2010.
 
The panel at the time had asked Glaxo to commission a re-examination of a large study of Avandia, called RECORD, to better assess the drug's safety. It also asked Glaxo to devise a means of better controlling availability and use of the drug, called a Risk Evaluation and Mitigation Strategy plan.
 
"We haven't asked for any changes in the drug label or in distribution for Avandia," Rhyne said. Moreover, she said Glaxo had not requested the planned June meeting of the FDA's Endocrinologic and Metabolic advisory panel, which will be held jointly with the FDA's Drug Safety and Risk Management Advisory committee.
 
Rhyne said a group of medical experts from Duke University has re-examined the RECORD study and recently submitted its findings to the FDA. She said it found there was no significant difference in cardiovascular safety between Avandia and two other types of widely used oral drugs - metformin and sulfonylureas.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

700 Babies Possibly Exposed to TB at Texas Hospital

Friday, 19 Sep 2014 23:45 PM

More than 700 infants may have been exposed to tuberculosis at an El Paso hospital over the past year by an employee rec . . .

Did FDA Food-Dragging Delay New Diet Pill Approval?

Friday, 19 Sep 2014 17:24 PM

The FDA's approval of the new diet pill Contrave could have come more than three years ago, an agency critic argues. . . .

Simple Test Detects Alzheimer's Early

Friday, 19 Sep 2014 17:18 PM

York University researchers have devised a simple test that combines thinking and movement can help to detect a person's . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved